The Bioanalytical group at ChemPartner offers high-quality services for qualitative and quantitative drug, metabolite and biomarker analysis in a variety of matrices. We routinely develop methods to support biology and pharmacology studies, including methods for oncology to identify hundreds of metabolites semi-quantitatively. Several LC/MS methods have been set up to replace biochemical and cell assays because of mass spectrometry specificity and sensitivity.
Our state-of-the-art laboratories have the latest instrumentation such as G2-S QTof and API6500. Our internationally-trained scientists have developed more than 1000 methods for Discovery support and biomarker analysis. We have also developed extensive methods adhering to FDA guidelines for GLP or clinical sample analysis. We routinely add new analytical methods to support preclinical and clinical PK and biomarker studies for our pharma and biotech clients’ compounds discovered at ChemPartner. We also perform TK analysis in support of GLP preclinical safety assessments.
Using mass spectrometry, we routinely provide sample analysis for in vitro ADME and PK studies such as Metabolite ID, phenotyping of drug-metabolizing enzymes, assessments of P450 inhibition and induction and PK evaluation in laboratory animals.